VG-201 is under clinical development by Virogin Biotech and currently in Phase I for Salivary Gland Cancer. According to GlobalData, Phase I drugs for Salivary Gland Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VG-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VG-201 is under development for the treatment of CEA high solid tumors including duodenal cancer, pancreatic cancer, ovarian cancer, leiomyosarcoma, salivary gland cancer, hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), colorectal cancer, colon cancer, non-small cell lung cancer, neuroendocrine cancer, solid tumors. It is administered by intratumor and intravenous route. The therapeutic candidate is an oncolytic virus with payloads IL12 and IL15/IL15Ralpha. It is developed based on Transcription and Translation Dual Regulated (TTDR) oncolytic virus platform.
Virogin Biotech overview
Virogin Biotech is a pharmaceutical company. It develops immunotherapies and oncolytic virotherapies that improve systemic antitumor immunity using oncolytic HSV-1 platform and Prime-Boost Approach. The company’s pipeline products include VG161, VG201, VG203, VG301, VGXXX. Its pipeline candidates treat Attenuated (ICP 34.5 deletion), and tumors. The company works in collaboration with research institutes, biotechnology, and pharmaceutical companies. It operates research and development hubs in Vancouver, Canada; and Shanghai, China. Virogin Biotech is headquartered in Vancouver, British Colombia, Canada.
For a complete picture of VG-201’s drug-specific PTSR and LoA scores, buy the report here.